eligibility_summary
Eligible: adults ≥18 with HER2+ (IHC 3+ or 2+/ISH+) advanced/metastatic breast cancer, prior T-DXd with progression, measurable disease (RECIST v1.1), ECOG 0–1, adequate marrow/organ function, life expectancy ≥12 weeks, consent. Exclude: prior disitamab vedotin, active infection, ILD/pneumonitis needing steroids, uncontrolled cardiovascular disease, pregnancy/lactation, other active cancers (unless disease-free ≥5y), other trials, or safety/compliance concerns.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II RADIANT-BC01 in HER2-positive metastatic breast cancer post–trastuzumab deruxtecan tests: 1) Disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate with a cathepsin-cleavable linker delivering MMAE (microtubule inhibitor), combined with 2) Bevacizumab, an anti-VEGF monoclonal antibody inhibiting angiogenesis, or 3) Pyrotinib, an oral irreversible pan-HER tyrosine kinase inhibitor (EGFR/HER2/HER4) that suppresses PI3K–AKT and MAPK signaling. Targets/pathways: HER2-overexpressing tumor cells (ADC binding/internalization), microtubules (MMAE cytotoxicity), VEGF/VEGFR axis in endothelial/tumor vasculature (anti-angiogenesis), and HER-family signaling (EGFR/HER2/HER4) with downstream PI3K/AKT and MAPK pathways to counter resistance.